Jennifer Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer Lee has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Catherine J. Wu
Dana-Farber Cancer Institute
31 shared publications - Christina Coppola
Center for Biomedical Informatics & Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
31 shared publications - David R. Patton
Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD
31 shared publications - David Sims
National Cancer Institute, Frederick, MD, United States
31 shared publications - Donna Brunnquell
Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD
31 shared publications - Jacob Gross
Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD
31 shared publications
Latest Publications
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Summary of evidence evaluating potential predictive biomarkers of response to immune checkpoint blockade in patients with MSI-H non-colorectal cancer tumors
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Summary of evidence evaluating potential predictive biomarkers of response to immune checkpoint blockade in patients with MSI-H non-colorectal cancer tumors
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
EnrichR results of top mutant genes from MutSig2CV
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
EnrichR results of top mutant genes from MutSig2CV
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Baseline characteristics for patients with (in) or without (out) molecular data
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Baseline characteristics for patients with (in) or without (out) molecular data
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Gene mutation profile in the cohort with corresponding clinical benefit status, MSI score, best confirmed response and TMB score
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Differences in infiltrating immune cell populations as determined by multiplex immunofluorescence among subjects with and without clinical benefit
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Subject MSI and MANTIS score correlation
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Subject MSI and MANTIS score correlation
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Representativeness of study participants
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
Representativeness of study participants
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
RNAseq Expression analysis using GSEA
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Next-Generation Sequencing–Based MSI Scoring Predicts Benefit in Mismatch Repair–Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D
RNAseq Expression analysis using GSEA